Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients

Abstract

Older acute myeloid leukemia (AML) patients have a poor prognosis; therefore, novel therapies are needed. Allogeneic natural killer (NK) cells have been adoptively transferred with promising clinical results. Here, we report the first-in-human study exploiting a unique scalable NK-cell product generated from CD34 hematopoietic stem and progenitor cells (HSPC) from partially HLA-matched umbilical cord blood units. Ten older AML patients in morphologic complete remission received an escalating HSPC-NK cell dose (between 3 and 30 × 10/kg body weight) after lymphodepleting chemotherapy without cytokine boosting. HSPC-NK cell products contained a median of 75% highly activated NK cells, with <1 × 10 T cells/kg and <3 × 10 B cells/kg body weight. HSPC-NK cells were well tolerated, and neither graft-versus-host disease nor toxicity was observed. Despite no cytokine boosting being given, transient HSPC-NK cell persistence was clearly found in peripheral blood up to 21% until day 8, which was accompanied by augmented IL15 plasma levels. Moreover, donor chimerism up to 3.5% was found in bone marrow. Interestingly, HSPC-NK cell maturation was observed, indicated by the rapid acquisition of CD16 and KIR expression, while expression of most activating receptors was sustained. Notably, 2 of 4 patients with minimal residual disease (MRD) in bone marrow before infusion became MRD negative (<0.1%), which lasted for 6 months. These findings indicate that HSPC-NK cell adoptive transfer is a promising, potential "off-the-shelf" translational immunotherapy approach in AML. .

The Transcription Factor ZNF683/HOBIT Regulates Human NK-Cell Development

“…Here, we used a feeder cell-free ex vivo system for the generation of human NK cells from cord blood HSCs (29). This system can generate therapeutic NK cells that have been proven to be safe in a phase I clinical trial (42). We have, furthermore, demonstrated that the NK cells formed using this system display the typical NK cell receptors, potent ADCC and produce IFN-γ similar to peripheral blood NK cells (28).…”

The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments

“…UCB-NK-cell infusions were safe and well tolerated without signs of GvHD. Interestingly, UCB-NK cells expressing low levels of KIRs and CD16a at the end of the ex vivo culture, underwent further maturation post-transfer in vivo , resulting in the upregulation of KIRs and CD16a, but continued to preserve the activated phenotype denoted by high expression of NKp30, NKp44, NKp46, NKG2D, and DNAM (73). …”

Challenges of NK cell-based immunotherapy in the new era

“…In patients who have reached CR or morphologic CR, adoptive NK cell transfer can remarkably prolong disease-free progression. Of the 28 patients reported, 4 had CR lasting for about 1 year, 5 had CR lasting for about 1.5 years, and 10 had CR lasting for about 2 years [62][63][64]. Meanwhile, 24 out of 50 patients with active diseases reached CR [55,58,[65][66][67].…”